0001326732-24-000012.txt : 20240409 0001326732-24-000012.hdr.sgml : 20240409 20240409082044 ACCESSION NUMBER: 0001326732-24-000012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240409 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xencor Inc CENTRAL INDEX KEY: 0001326732 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 201622502 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36182 FILM NUMBER: 24831204 BUSINESS ADDRESS: STREET 1: 465 N. HALSTEAD ST. STREET 2: SUITE 200 CITY: PASADENA STATE: CA ZIP: 91107 BUSINESS PHONE: 626-305-5900 MAIL ADDRESS: STREET 1: 465 N. HALSTEAD ST. STREET 2: SUITE 200 CITY: PASADENA STATE: CA ZIP: 91107 8-K 1 xncr-20240409.htm 8-K xncr-20240409

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  April 9, 2024
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
File Number)
(IRS Employer
Identification Number)
465 North Halstead Street, Suite 200
(Address of principal executive offices)
(Zip Code)
(626) 305-5900
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareXNCRNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Executive Officer

On October 24, 2023, John Kuch, Senior Vice President and Chief Financial Officer, notified Xencor, Inc. (the “Company”) of his intention to retire from the Company effective March 31, 2024. Effective on April 9, 2024, Mr. Kuch will step down from his role as Chief Financial Officer of the Company. He will continue to be employed by the Company in a non-executive capacity and has agreed to enter into a consulting agreement with the Company at a later date.

(c) Appointment of Executive Officer

As previously announced, on April 9, 2024 (the “Start Date”), Mr. Bart Cornelissen, age 46, was appointed as Senior Vice President and Chief Financial Officer of the Company for an indefinite term.

Prior to joining the Company, Mr. Cornelissen served as vice president, corporate finance at Seagen Inc. (“Seagen”), where he built and scaled the corporate finance organization to support revenue growth and dealmaking activity, including multiple licensing transactions and the company’s $43 billion acquisition by Pfizer in 2023. Before Seagen, Mr. Cornelissen served as vice president, finance for the END Fund while at the Bill & Melinda Gates Foundation, where he enhanced the fund’s financial analysis and strategic decision-making capabilities. At the Gates Foundation he was also the finance lead for malaria and neglected tropical disease initiatives, where he guided new investments for major drug and vaccine development partnerships. Earlier in his career, Mr. Cornelissen provided leadership to multiple finance teams in Austria, Germany and Switzerland, at DSM Nutritional Products, a former division of Roche. He began his career within the life sciences and global health sectors at Novartis, in roles of increasing responsibility within global financial planning and analysis. Mr. Cornelissen received his M.Sc. in Business Administration from the Rotterdam School of Management at Erasmus University.

In accordance with the Company’s offer of an appointment to the position of Senior Vice President and Chief Financial Officer, Mr. Cornelissen is entitled to receive an initial annual base salary of $465,000.00 as well as eligibility for discretionary salary increases and an annual discretionary bonus opportunity of 45% of annual base salary. Mr. Cornelissen may be eligible for annual refresher grants of stock options, restricted stock units (“RSU”), or both, at the Company’s sole discretion.

Mr. Cornelissen will be entitled to receive a grant consisting of options to purchase 190,194 shares of the Company’s common stock (the “Common Stock”) with an aggregate option value of $2,250,000 pursuant to the Company’s 2023 Equity Incentive Plan (the “2023 Plan”), one-fourth of which shares will vest on the one-year anniversary of the Start Date and the balance of the option shares shall vest at the rate of 1/48th on the final date of each month thereafter, subject to Mr. Cornelissen’s continuous service through each such vesting date.

Mr. Cornelissen will be entitled to receive a Restricted Stock Unit (“RSU”) grant consisting of RSU shares of Common Stock valued at approximately $1,000,000 pursuant to the 2023 Plan. The RSUs will vest over a period of three (3) years following the grant date with 1/3rd of the RSUs vesting on each of the first (1st), second (2nd) and third (3rd)-year anniversaries of the grant date, so long as Mr. Cornelissen remains continuously employed by the Company.

Mr. Cornelissen will be entitled to receive executive perquisites, fringe and other benefits as are provided to other similarly-situated officers under any of the Company’s plans and/or programs in effect from time to time and shall be eligible to participate in those various Company benefit plans, practices and policies in place during the term of his employment to the extent allowed under and in accordance with the terms of those plans, as well as in any other benefit plans the Company offers to similarly-situated officers or other employees from time to time during the term of his employment.

In addition, in the event the Company terminates Mr. Cornelissen’s employment without Cause, as defined in the 2023 Plan or its successors, or he resigns for “Good Reason,” as defined below, he will be eligible for the following benefits: (1) a cash payment equivalent to twelve (12) months of his base salary at the rate in effect as of the effective date of such termination; and (2) if he is eligible for and timely elects continued group health plan coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) following his termination, the Company will pay his COBRA group health insurance premiums for him and his eligible dependents until the earliest of (A) the close of the Twelve (12) month period following the termination of his employment (the “COBRA Payment Period”), (B) the expiration date of his eligibility for the continuation coverage under COBRA, or (C) the date when he becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment.


“Good Reason” is defined as the occurrence of any of the following events without Mr. Cornelissen’s consent: (a) any material reduction of, or material adverse change to his authority, duties, or responsibilities, where such material reduction in authority or job responsibilities is accompanied by a change in title; (b) a material reduction in his annual base salary, other than pursuant to a Company-wide reduction of annual base salaries for employees of the Company generally; or (c) the relocation of the Company’s executive offices by a distance of 50 miles or more, which relocation requires an increase in his one-way driving distance by more than 25 miles.

In the event the Company terminates Mr. Cornelissen’s employment without Cause or he resigns for Good Reason in connection with a Change in Control, as defined in the 2023 Plan or its successors, prior to the one year anniversary of his start date, then he shall be entitled to the following severance benefits: (1) a cash payment equivalent to twelve (12) months of his base salary at the rate in effect as of the effective date of such termination; and (2) the number of vested option shares and RSU shares available for him to immediately exercise shall be calculated as if he had remained employed by the Company for one (1) additional year. In the event the Company terminates his employment without Cause or he resigns for Good Reason in connection with a Change in Control that occurs after the one year anniversary of the Start Date, then he shall be entitled to the following severance benefits: (1) a cash payment equivalent to Twelve (12) months of his base salary at the rate in effect as of the effective date of such termination; and (2) all (100%) of his option shares and RSU shares shall be fully vested and immediately exercisable.

A termination of employment shall be deemed to be in connection with a Change in Control if it is initiated by the Company and is effective within ninety (90) days prior to or twelve (12) months after the effective date of the Change in Control of the Company. A resignation of employment shall be deemed to be in connection with a Change in Control if it is initiated by Mr. Cornelissen and is effective during the period beginning on the execution of a definitive written agreement that if consummated in accordance with its terms would result in a Change of Control and ending on the earlier of (1) the termination of such agreement, or (2) twelve (12) months following the consummation of a Change of Control pursuant to such agreement.

On April 9, 2024 the Company issued a press release which is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File (formatted as inline XBRL).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 9, 2024
By:/s/ Celia Eckert
Celia Eckert
General Counsel & Corporate Secretary
EX-99.1 2 xncr-20240409xexx991.htm EX-99.1 Document
Exhibit 99.1
Xencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif. -- April 9, 2024 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company’s transformation into a global, multi-product organization that generated over $2 billion in annual revenue.
“Bart’s exceptional track record in financial planning and analysis, business development and organizational excellence will be of great value to Xencor as we advance our maturing clinical-stage pipeline of drug candidates and continue to explore our XmAb® platforms against novel biology,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “Throughout his career, Bart has demonstrated collaborative leadership during periods of organizational growth, including in the run up to commercialization, as well as a dedication to improving health across the globe, and we are delighted that he has joined our team.”
As vice president, corporate finance at Seagen, Mr. Cornelissen built and scaled the corporate finance organization to support tremendous revenue growth and dealmaking activity, including multiple licensing transactions and the company’s $43 billion acquisition by Pfizer in 2023. Before Seagen, while at the Bill & Melinda Gates Foundation, he served as vice president, finance for the END Fund, through which he enhanced the fund’s financial analysis and strategic decision-making capabilities. He had also been the Gates Foundation’s finance lead for malaria and neglected tropical disease initiatives, where he guided new investments for major drug and vaccine development partnerships. Earlier in his career, Mr. Cornelissen provided leadership to multiple finance teams in Austria, Germany and Switzerland, at DSM Nutritional Products, a former division of Roche. He began his career within the life sciences and global health sectors at Novartis, in roles of increasing responsibility within global financial planning and analysis. Mr. Cornelissen received his M.Sc. in Business Administration from the Rotterdam School of Management at Erasmus University.
“Xencor has earned a longstanding reputation as a leader in protein engineering, with its XmAb technologies behind multiple products marketed by partners and collaborations that have continued to enable reinvestment in novel drug candidates for development,” said Mr. Cornelissen. “I am pleased to join Xencor to support planning and capitalization for the company’s growth, as its internal pipeline, focused on XmAb bispecific T cell engagers in oncology, advances through clinical development.”
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
Forward-Looking Statements
Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely

Exhibit 99.1
statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to the quotations from Xencor's president and chief executive officer, quotations from Xencor’s senior vice president and chief financial officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, in each case as described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2023 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Charles Liles
For Media:
Cassidy McClain
Inizio Evoke

EX-101.SCH 3 xncr-20240409.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 xncr-20240409_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 xncr-20240409_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 xencora.jpg begin 644 xencora.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Apr. 09, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 09, 2024
Entity Registrant Name XENCOR, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36182
Entity Tax Identification Number 20-1622502
Entity Address, Address Line One 465 North Halstead Street, Suite 200
Entity Address, City or Town Pasadena
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91107
City Area Code (626)
Local Phone Number 305-5900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol XNCR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001326732
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.xencor.com/role/Cover Cover Cover 1 false false All Reports Book All Reports xncr-20240409.htm xncr-20240409.xsd xncr-20240409_lab.xml xncr-20240409_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xncr-20240409.htm": { "nsprefix": "xncr", "nsuri": "http://www.xencor.com/20240409", "dts": { "inline": { "local": [ "xncr-20240409.htm" ] }, "schema": { "local": [ "xncr-20240409.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "xncr-20240409_lab.xml" ] }, "presentationLink": { "local": [ "xncr-20240409_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.xencor.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xncr-20240409.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "xncr-20240409.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.xencor.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001326732-24-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001326732-24-000012-xbrl.zip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end XML 18 xncr-20240409_htm.xml IDEA: XBRL DOCUMENT 0001326732 2024-04-09 2024-04-09 false 0001326732 8-K 2024-04-09 XENCOR, INC. DE 001-36182 20-1622502 465 North Halstead Street, Suite 200 Pasadena CA 91107 (626) 305-5900 false false false false Common Stock, par value $0.01 per share XNCR NASDAQ false